文献速递呼吸道感染呼吸危重症与机械通气

秋水仙碱治疗住院COVID-19患者(RECOVERY):随机对照开放标签平台试验

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
PubMed 文献 · Lancet Respir Med · 2021-10-18

BACKGROUND: Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitted to hospital with COVID-19.…

要点

  • 住院COVID-19患者使用秋水仙碱未降低28天死亡率。
  • 秋水仙碱未缩短住院时间或提高28天内出院比例。
  • 基线未接受有创机械通气者,进展至机械通气或死亡风险无差异。

核心结论

  • 在住院COVID-19成人中,秋水仙碱与28天死亡率、住院时间或进展至有创机械通气或死亡风险的降低均无关。

研究设计与样本

  • 精简随机对照开放标签平台试验,在177家英国医院、2家印度尼西亚医院和2家尼泊尔医院比较多种可能治疗与常规护理。
  • 主要终点为28天死亡率;所有分析按意向性治疗进行。

主要发现

  • 所有预设亚组结果一致。

临床怎么用

  • 住院COVID-19患者不应以降低28天死亡率、缩短住院时间或预防进展至有创机械通气为目的使用秋水仙碱。

局限性

  • 开放标签设计。
  • 结果仅适用于符合本试验入组条件的住院COVID-19成人。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitted to hospital with COVID-19. METHODS: In this streamlined, randomised, controlled, open-label trial, underway at 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Patients were eligible for inclusion in the study if they were admitted to hospital with clinically suspected or laboratory confirmed SARS-CoV-2 infection and had no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. Eligible and consenting adults were randomly assigned (1:1) to receive either usual standard of care alone (usual care group) or usual standard of care plus colchicine (colchicine group) using web-based simple (unstratified) randomisation with allocation concealment. Participants received colchicine 1 mg after randomisation followed by 500 μg 12 h later and then 500 μg twice a day by mouth or nasogastric tube for 10 days in total or until discharge. Dose frequency was halved for patients receiving a moderate CYP3A4 inhibitor (eg, diltiazem), patients with an estimated glomerular filtration rate of less than 30 mL/min per 1·73m2, and those with an estimated bodyweight of less than 70 kg. The primary outcome was 28-day mortality, secondary endpoints included time to discharge, the proportion of patients discharged from hospital within 28 days, and, in patients not on invasive mechanical ventilation at randomisation, a composite endpoint of invasive mechanical ventilation or death. All analyses were by intention-to-treat. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. FINDINGS: Between Nov 27, 2020, and March 4, 2021, 11 340 (58%) of 19 423 patients enrolled into the RECOVERY trial were eligible to receive colchicine; 5610 (49%) patients were randomly assigned to the colchicine group and 5730 (51%) to the usual care group. Overall, 1173 (21%) patients in the colchicine group and 1190 (21%) patients in the usual care group died within 28 days (rate ratio 1·01 [95% CI 0·93 to 1·10]; p=0·77). Consistent results were seen in all prespecified subgroups of patients. Median time to discharge alive (10 days [IQR 5 to >28]) was the same in both groups, and there was no significant difference in the proportion of patients discharged from hospital alive within 28 days (3901 [70%] patients in the colchicine group and 4032 [70%] usual care group; rate ratio 0·98 [95% CI 0·94 to 1·03]; p=0·44). In those not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (1344 [25%] in the colchicine group vs 1343 [25%] patients in the usual care group; risk ratio 1·02 [95% CI 0·96 to 1·09]; p=0·47). INTERPRETATION: In adults hospitalised with COVID-19, colchicine was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. FUNDING: UK Research and Innovation (Medical Research Council), National Institute of Health Research, and Wellcome Trust.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021. PMID: 34672950. doi:10.1016/S2213-2600(21)00435-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。